IP Library Patent Application 12428399
Patent Application
App. No. 12/428,399

Novel Polymorphs of Azabicyclohexane

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/428,399
Abstract

The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.

Claims (105)

1 . A polymorph of an acid addition salt of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in crystalline form substantially free of other geometric, optical and polymorphic isomers thereof.

2 . The acid addition salt of claim 1 wherein said salt is a hydrochloride salt.

3 . The polymorph form A of an acid addition salt of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in crystalline form substantially free of other geometric, optical and polymorphic isomers thereof.

4 . The polymorph form A of claim 3 wherein said acid addition salt is a hydrochloride salt.

5 . The polymorph form A of claim 4 wherein the X-ray powder diffraction pattern of said polymorph, as measured at crystal sizes of from about 10 to 40 microns, is characterized by peaks at one or more of and at about the following °2θ (degree) values:

17.14;

19.62;

21.96;

24.52; and

26.74.

6 . The polymorph form A of claim 4 wherein the X-ray powder diffraction pattern of said polymorph, as measured at crystal sizes of from about 10 to 40 microns, is characterized by peaks at all of and at about the following °2θ (degree) values:

17.14;

19.62;

21.96;

24.52; and

26.74.

7 . The polymorph form A of claim 4 wherein the Raman spectrum of said polymorph is characterized by peaks at one or more of and at about the following wavenumbers (cm −1 ):

762;

836;

921;

959:

1393;

1597;

2890;

2982; and

3064.

8 . The polymorph form A of claim 4 wherein the Raman spectrum of said polymorph is characterized by peaks at all of and at about the following wavenumbers (cm −1 ):

762;

836;

921;

959;

1393;

1597;

2890;

2982; and

3064.

9 . The polymorph form B of an acid addition salt of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in crystalline form substantially free of other geometric, optical and polymorphic isomers thereof.

10 . The polymorph form B of claim 9 wherein said acid addition salt is a hydrochloride salt.

11 . The polymorph form B of claim 10 wherein the X-ray powder diffraction pattern of said polymorph, as measured at crystal sizes of from about 10 to 40 microns, is characterized by peaks at one or more of and at about the following °2θ (degree) values:

15.58;

17.52;

21.35;

23.04;

25.43; and

30.72.

12 . The polymorph form B of claim 10 wherein the X-ray powder diffraction pattern of said polymorph, as measured at crystal sizes of from about 10 to 40 microns, is characterized by peaks at all of and at about the following °2θ (degree) values:

15.58;

17.52;

21.35;

23.04;

25.43;

and 30.72.

13 . The polymorph form B of claim 10 wherein the Raman spectrum of said polymorph is characterized by peaks at one or more of and at about the following wavenumbers (cm −1 ):

1245;

1380;

2963;

2993;

3027; and

3066.

14 . The polymorph form B of claim 10 wherein the Raman spectrum of said polymorph is characterized by peaks at all of and at about the following wavenumbers (cm −1 ):

1245;

1380;

2963;

2993;

3027; and

3066.

15 . The polymorph form C of an acid addition salt of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in crystalline form substantially free of other geometric, optical and polymorphic isomers thereof.

16 . The polymorph form C of claim 15 wherein said acid addition salt is a hydrochloride salt.

17 . The polymorph form C of claim 16 wherein the X-ray powder diffraction pattern of said polymorph, as measured at crystal sizes of from about 10 to 40 microns, is characterized by peaks at one or more of and at about the following °2θ (degree) values:

13.34;

17.64;

20.07;

21.32;

22.97;

24.86;

26.32; and

27.90.

18 . The polymorph form C of claim 16 wherein the X-ray powder diffraction pattern of said polymorph, as measured at crystal sizes of from about 10 to 40 microns, is characterized by peaks at all of and at about the following °2θ (degree) values:

13.34;

17.64;

20.07;

21.32;

22.97;

24.86;

26.32; and

27.90.

19 . The polymorph form C of claim 16 wherein the Raman spectrum of said polymorph is characterized by peaks at one or more of and at about the following wavenumbers (cm −1 ):

1059;

1094;

1266;

1343;

1595;

2966;

2900; and

3070.

20 . The polymorph form C of claim 16 wherein the Raman spectrum of said polymorph is characterized by peaks at all of and at about the following wavenumbers (cm −1 ):

1059;

1094;

1266;

1343;

1595;

2966;

2900; and

3070.

21 - 65 . (canceled)

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2018
From: EUTHYMICS BIOSCIENCE, INC.
To: ETHISMOS RESEARCH, INC.
Reel/Frame 045252/0870 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2014
From: HAGEN, ERIC J.; HALLORAN, KEVIN
To: DOV PHARMACEUTICAL, INC.
Reel/Frame 032933/0993 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2014
From: HAGEN, ERIC J.; HALLORAN, KEVIN
To: EUTHYMICS BIOSCIENCE, INC.
Reel/Frame 032934/0157 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2014
From: HAGEN, ERIC J.; HALLORAN, KEVIN
To: DOV PHARMACEUTICAL, INC.
Reel/Frame 032260/0388 →
CHANGE OF NAME Recorded Feb 20, 2014
From: DOV PHARMACEUTICAL, INC.
To: EUTHYMICS BIOSCIENCE, INC.
Reel/Frame 032260/0504 →